Holger Zimmermann replaces founding chief executive of AiCuris

AiCuris, a company formed by experts from Bayer's (BAYN: DE) virology and bacteriology research divisions, is to have a lineup change in its senior management.

Helga Rübsamen-Schaeff will move from chief executive officer to chair of the board as of March 1, and the current chief scientific officer, Holger Zimmermann will replace her. Dr Zimmermann has been working with Prof Rübsamen-Schaeff to develop innovative resistance-breaking drugs against infectious diseases since the company’s formation in 2006.

Dr Zimmermann said: "During the past nine years, Prof Rübsamen- Schaeff transformed AiCuris from a spin-off into a globally renowned company. In 2012, under her leadership, AiCuris achieved one of the largest license agreements to-date in the European biotech industry. I am therefore very pleased that we will continue to profit from her extensive expertise as she assumes her role of chair of the board following the hand-over of operative business.”